Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › moxifloxacin

moxifloxacin

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of moxifloxacin

67 trials tracked of moxifloxacin: 17 in phase 3 or 4 and 6 with published results. The most-cited published study has 462 citations.

67Trials tracked
17Phase 3 & 4
0Recruiting
6With published results
Phase distribution
Phase 4 6 Phase 3 11 Phase 2 11 Phase 1 36 Other / NA 3
  1. Phase 4 Alternative Antibiotic Regime in the Treatment of GAgP Completed · 462 cited
  2. Phase 3 The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB Completed · 402 cited
  3. Phase 3 Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13) Completed · 229 cited
  4. Phase 3 Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia Completed · 142 cited
  5. Phase 3 Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia Completed · 108 cited
  6. Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients Completed · 53 cited
Show 44 more trials
  1. Phase 4 Aqueous Absorption and Pharmacokinetics of Besivance Versus VIGAMOX in Patients Undergoing Phacoemulsification Completed
  2. Phase 4 Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants Completed
  3. Phase 4 Moxifloxacin vs. Polytrim for Conjunctivitis Completed
  4. Phase 4 Study of AzaSite (Azithromycin) Versus Vigamox in the Conjunctiva of Healthy Volunteers Completed
  5. Phase 4 Evaluation of Whether Deferiprone Affects QT Interval in Healthy Subjects Completed
  6. Phase 3 Shortening Treatment by Advancing Novel Drugs Completed
  7. Phase 3 Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia Completed
  8. Phase 3 Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia Completed
  9. Phase 3 Moxifloxacin in the Prevention of Bacteremia After High-dose Chemotherapy and Transplantation of Peripheral Stem Cells Completed
  10. Phase 3 A Trial To Evaluate Two Antibiotics For The Treatment Of Acute Exacerbation Of Chronic Bronchitis (AECB) Completed
  11. Phase 3 A Study to Evaluate Efficacy and Safety Profile of Zabofloxacin Tablet 400mg and Moxifloxacin Tablet 400mg Completed
  12. Phase 2 Evaluation of SQ109, High-dose Rifampicin, and Moxifloxacin in Adults With Smear-positive Pulmonary TB in a MAMS Design Completed
  13. Phase 2 Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis Completed
  14. Phase 2 Essentiality of INH in TB Therapy Completed
  15. Phase 2 A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial Completed
  16. Phase 2 Evaluation of Early Bactericidal Activity in Pulmonary Tuberculosis With(J-M-Pa-Z) (NC-001) Completed
  17. Phase 2 Improving Retreatment Success (IMPRESS) Completed
  18. Phase 2 Moxifloxacin As Part of a Multi-Drug Regimen For Tuberculosis Completed
  19. Phase 2 Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes Completed
  20. Phase 2 A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis. Completed
  21. Phase 2 A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes Completed
  22. Phase 2 A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Completed
  23. Phase 1 A Study of LY2484595 on the Electrical Activity of the Heart Completed
  24. Phase 1 Placebo-Corrected Effects of Therapeutic Dose (100 mg) and Supratherapeutic Dose (300 mg) of ITF2357 (Givinostat) and Moxifloxacin on QT/QTC Interval Completed
  25. Phase 1 Guanfacine Immediate-release Electrocardiogram Results (QTc) Study Completed
  26. Phase 1 Thorough QT Study of Intravenous Amisulpride Completed
  27. Phase 1 Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects Completed
  28. Phase 1 To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers Completed
  29. Phase 1 Assessment of the Effect of Empagliflozin (BI 10773) as Single Dose on the QT Interval in Healthy Female and Male Subjects Completed
  30. Phase 1 Phase I Study of OPC-61815 Completed
  31. Phase 1 A Study of Effect of Selpercatinib (LY3527723) on Corrected QT (QTc) Interval in Healthy Participants Completed
  32. Phase 1 A Study to Investigate the Effects of Sisunatovir on QTc Interval in Healthy Adult Participants. Completed
  33. Phase 1 Trial to Evaluate the Effects of OPC-34712 on QT/QTc in Subjects With Schizophrenia or Schizoaffective Disorder Completed
  34. Phase 1 A Study of the Cardiac Effects of ALXN1840 in Healthy Adults Completed
  35. Phase 1 Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects Completed
  36. Phase 1 Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers Completed
  37. Phase 1 Trial to Evaluate the Effect of Eslicarbazepine Acetate on Cardiac Repolarization Completed
  38. Phase 1 A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia Completed
  39. Phase 1 A Study in Healthy People to Test Whether Different Doses of BI 1015550 Have Potential to Induce Heart Rhythm Abnormalities Completed
  40. Phase 1 Effect of Anagrelide Hydrochloride on Any Changes in Heart Function in Healthy Volunteers Completed
  41. Phase 1 A TQT Study of Effect of M2951 on Cardiac Repolarization Completed
  42. Phase 1 This Study in Healthy Men and Women Tests Whether BI 409306 Has an Effect on the ECG (Thorough QT Study) Completed
  43. Phase 1 Effects of HSK3486 on Cardiac Repolarization in Health Subjects (TQT) Completed
  44. Phase 1 A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People Completed

Showing the 50 most-cited and recently-updated of 67 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Quadruple antimycobacterial regimen achieves clinical stability in cystic fibrosis patient with M. abscessus
Pediatrics Sys. Review
Quadruple antimycobacterial regimen achieves clinical stability in cystic fibrosis patient with M. abscessus Case report shows quadruple regimen for cystic fibrosis infection
A case report and literature review describes a 21-year-old man with cystic fibrosis and Mycobacterium abscessus infection who achieved clin…
A young man with cystic fibrosis and a hard-to-treat infection achieved stability using a four-drug antimycobacterial regimen.
Frontiers Jun 2, 2026
Nemonoxacin shows similar efficacy to moxifloxacin in hospitalized CAP patients
Drug Pipeline Cohort
Nemonoxacin shows similar efficacy to moxifloxacin in hospitalized CAP patients New pneumonia drug saves money while matching standard care results
This retrospective cohort study of 196 hospitalized patients with community-acquired pneumonia found that nemonoxacin injection had 100.0% c…
A new pneumonia drug saves hospital costs while working just as well as the standard treatment for patients.
Frontiers Apr 29, 2026